Source: UniDoc Health.
  • UniDoc (UDOC) has successfully concluded a series of pilot trials with OnPharm-United
  • OnPharm-United is ready to progress to contract UniDoc’s services including development of roll-out details, locations, and timelines to its network of pharmacies throughout Ontario
  • The company intends to enter into a business agreement with OnPharm-United as soon as commercially possible
  • UniDoc (UDOC) is unchanged trading at $1.06 per share at 09:55 am ET

UniDoc (UDOC) has successfully concluded a series of pilot trials with OnPharm-United.

Both companies agreed to jointly offer a health care and virtual care platform solution exclusively to the entire OnPharm-United network in Ontario.

OnPharm-United is ready to progress to contract UniDoc’s services including development of roll-out details, locations, and timelines to its network of pharmacies throughout Ontario.

UniDoc’s CEO, Antonio Baldassarre called this a significant achievement for everyone involved with this growing venture.

“Acceptance by OnPharm-United is an important validation of our concept and launches us directly into an important segment of the domestic healthcare sector. We are extremely pleased that the test was a success and look forward to working with the OnPharm-United team to finalize the next steps and advance our transition from a domestic development phase into active operations in one of the busiest marketplaces in Canada.”

The company intends to enter into a business agreement with OnPharm-United as soon as commercially possible

OnPharm is a network of independent pharmacies in Canada.

UniDoc Health is developing a personal remote virtual kiosk for the delivery of telehealth.

UniDoc (UDOC) is unchanged trading at $1.06 per share at 09:55 am ET.


More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.